Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical study of regorafenib combined with PD-1/PD-L1 monoclonal antibody and local c-TACE in the treatment of MSS advanced colorectal cancer with liver metastasis
ChiCTR2300068003Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of regorafenib in colorectal cancer (CRC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Objective Response Rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300068003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068003.